Structural Plasticity of an HIV-1 Nef/Pak-2 Activity Surface

HIV-1 Nef/Pak-2 活性表面的结构可塑性

基本信息

项目摘要

DESCRIPTION (provided by applicant): Nef is a major determinant of pathogenesis; both human and simian immunodeficiency viruses (HIV/SIV) show an attenuated phenotype when the accessory protein Nef is deleted. In vitro, both HIV and SIV Nef demonstrate several activities which include enhancement of infectivity, CD4 and MHCI downregulation and the activation of p21-activated protein kinase 2 (Pak-2) among others. Interestingly, Nef achieves all these activities in the face of high sequence divergence. It has been suggested that the complex biology of Nef is regulated through conformational changes induced by its cellular location and specific protein-protein interactions during cell traffic. In order to understand the importance of each of the Nef-mediated activities, in particular the activation of the host cell kinase Pak-2 to HIV/SIV pathogenesis, we have identified a surface on the subtype B Nef molecule that is specific for this activity. However, analysis of the amino acid sequence of subtype E Nef sequences indicated that dramatically different amino acid substitutions in this surface that completely abolish the ability of subtype B Nef to activate Pak-2 result in fully functional subtype E Nefs. Our biochemical analysis together with in silico modeling of Nef structure resulted in the identification of compensatory mutations that restore Nef activity. As part of this grant we first propose to identify these compensatory mutations in Nef from additional HIV-1 subtypes to fully define this surface and secondly to extend these observations to SIV Nef. We propose to identify alternative structures of this surface as it relates to variation between subtypes and even between strains. We will compile sequences in all available databases and translate our observations by generating mutated versions of the prototypical SF2 Nef that reflect naturally occurring sequences. The effect of these substitutions to the Nef-mediated activities, particularly the activation of Pak-2, will be correlated with changes in the tridimensional structure of Nef. The studies proposed here will help elucidate the structural requirements for the activation of Pak-2 by Nef and will serve as the basis for future in vivo experiments aimed at characterizing its functional significance.
描述(由申请方提供):Nef是发病机制的主要决定因素;当辅助蛋白Nef缺失时,人类和猿免疫缺陷病毒(HIV/SIV)均显示减毒表型。在体外,HIV和SIV Nef都表现出几种活性,其中包括增强感染性、CD 4和MHCI下调以及激活p21活化的蛋白激酶2(Pak-2)等。有趣的是,Nef在面对高序列差异时实现了所有这些活动。有人认为,Nef的复杂生物学是通过其细胞位置和特定的蛋白质-蛋白质相互作用在细胞运输过程中诱导的构象变化来调节的。为了理解每种Nef介导的活性的重要性,特别是宿主细胞激酶Pak-2对HIV/SIV发病机制的活化,我们已经鉴定了亚型B Nef分子上特异于该活性的表面。然而,亚型E Nef序列的氨基酸序列的分析表明,在该表面中完全消除亚型B Nef激活Pak-2的能力的显著不同的氨基酸取代导致完全功能的亚型E Nef。我们的生化分析与Nef结构的计算机模拟一起鉴定了恢复Nef活性的补偿突变。作为这项资助的一部分,我们首先建议从其他HIV-1亚型中识别Nef中的这些补偿性突变,以充分定义这种表面,其次将这些观察结果扩展到SIV Nef。我们建议确定替代结构的表面,因为它涉及到亚型之间的变化,甚至菌株之间。我们将在所有可用的数据库中编译序列,并通过生成反映自然发生序列的原型SF 2 Nef的突变版本来翻译我们的观察结果。这些取代对Nef介导的活性的影响,特别是Pak-2的活化,将与Nef的三维结构的变化相关。这里提出的研究将有助于阐明Pak-2激活Nef的结构要求,并将作为未来体内实验的基础,旨在表征其功能意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

J. Victor Garcia-Martinez其他文献

J. Victor Garcia-Martinez的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('J. Victor Garcia-Martinez', 18)}}的其他基金

Development of sustained release/long acting products for TB
开发结核病缓释/长效产品
  • 批准号:
    10989407
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Development of sustained release/long acting products for TB
开发结核病缓释/长效产品
  • 批准号:
    10882260
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice
探索新型阻断剂和联合用药在人源化小鼠中缓解 HIV
  • 批准号:
    10714365
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Impact of the gastrointestinal microbiome on HIV reservoirs
胃肠道微生物组对 HIV 储存库的影响
  • 批准号:
    10491166
  • 财政年份:
    2021
  • 资助金额:
    $ 19.06万
  • 项目类别:
Impact of the gastrointestinal microbiome on HIV reservoirs
胃肠道微生物组对 HIV 储存库的影响
  • 批准号:
    10669232
  • 财政年份:
    2021
  • 资助金额:
    $ 19.06万
  • 项目类别:
Impact of the gastrointestinal microbiome on HIV reservoirs
胃肠道微生物组对 HIV 储存库的影响
  • 批准号:
    10374223
  • 财政年份:
    2021
  • 资助金额:
    $ 19.06万
  • 项目类别:
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention
用于治疗和预防艾滋病毒的下一代超长效抗逆转录病毒制剂
  • 批准号:
    10877335
  • 财政年份:
    2018
  • 资助金额:
    $ 19.06万
  • 项目类别:
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention
用于治疗和预防艾滋病毒的下一代超长效抗逆转录病毒制剂
  • 批准号:
    10228741
  • 财政年份:
    2018
  • 资助金额:
    $ 19.06万
  • 项目类别:
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention
用于治疗和预防艾滋病毒的下一代超长效抗逆转录病毒制剂
  • 批准号:
    10468909
  • 财政年份:
    2018
  • 资助金额:
    $ 19.06万
  • 项目类别:
Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention
用于治疗和预防艾滋病毒的下一代超长效抗逆转录病毒制剂
  • 批准号:
    9790934
  • 财政年份:
    2018
  • 资助金额:
    $ 19.06万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Continuing Grant
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
    Studentship
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 19.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了